Article Page

Abstract

Immune response, and clinicalresponse in melanoma patients after combined therapy with temozolomide and the telomerase peptide vaccine GV1001 in previous GV1001 trials showed immune responses in approximately 60% of lung orpancreatic cancer patients. Previous Experimental Studies Twenty-five subjects with advanced stage IV melanoma (M1B or M1C) received concomitant temozolomide and GV1001. Temozolomide was administered 200 mg/m2 orally for 5 daysevery fourth week, and GV1001 as eight injections over 11 weeks. Immune response was evaluated bydelayed type hypersensitivity, T-cell proliferation, and cytokine assays. The immunologic responders continued monthly vaccination. Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc. Natl Acad. Sci. USA, 105, 5441–5446]. A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics, 25, i305–i312.]. These algorithms have been extensively benchmarked and shown to outperform most existing algorithms. Moreover, several predictions resulting from SMAP-WS have been validated experimentally. Thus far SMAP-WS has been applied to predict drug side effects, and to repurpose existing drugs for new indications. SMAP-WS provides both a user-friendly web interface and programming API for scientists to address a wide range of compute intense questions in biology and drug discovery. Here, in Biogenea we have for the first generated an in silico Telomerase Peptide mimotopic poly-chemo structure simulator eith promising clinical results in Stage IV Melanoma Patients when combined with Temozolamide using the BiogenetoligandorolTM and the SMAP-WS. A parallel web service for structural proteome-wide ligand-binding site comparison.

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) A Telomerase Peptide Vaccination simulated poly-chemo mimotopic pharmacological structure Combined with Temozolomide as a novel in silico promising anti-cancer drug-like agent in Stage IV Melanoma Patients generated by the BiogenetoligandorolTM based parallel web service for structural proteome-wide multi-targeted ligand-binding conserved binding pharmacophoric site comparison.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available